Scholarlink

<p>This study (<i>n</i> = 668) investigated the effect of vaccination on SARS-CoV-2 infection among individuals with type 2 diabetes mellitus (T2DM), cancer, and smoking in a prospective cohort study in Northern Germany. Participants from the SHIP-COVID cohort were followed from October 2020 to October 2022 using repeated questionnaires and serological tests. Infection was defined by anti-nucleocapsid (anti-NCP) antibodies’ detection, self-reported Real Time Polymerase Chain Reaction (RT-PCR) or rapid antigen test. Vaccine efficacy was evaluated using risk differences (RD), risk ratios (RR), p-values, and 95% confidence intervals. Infection risk decreased with more vaccine doses; the 3rd (RR = 0.68) and 4th (RR = 0.29) doses offered significant protection. Both sexes showed protection with 3rd and 4th doses (RR = 0.67 and 0.20 in women and 0.68 and 0.39 in men, respectively). Logistic regression showed higher infection odds in individuals with T2DM (14%) and cancer (68% in SHIP-START-3 dataset and 45% in SHIP-START-4 dataset), while current smokers had 47% and 45% lower odds than non-smokers in SHIP-START-3 and SHIP-START-4 datasets respectively. No significant interactions were found between vaccination and T2DM, cancer, or smoking.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

COVID-19 vaccination lowers SARS-CoV-2 infection risk independent of diabetes, cancer and smoking in SHIP-COVID cohort, Northern Germany

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月7日

查看全文
  • Muhammad Nasir Khan Khattak,
  • Josefin Pauline Haß,
  • Till Ittermann,
  • Marcus Dörr,
  • Ola Sidahmed,
  • Niels Ole Kristiansen,
  • Lena Ulm,
  • Kathrin Lehmann,
  • Karsten Becker,
  • Tillman Görig,
  • Nils-Olaf Hübner,
  • Henry Völzke

摘要

This study (n = 668) investigated the effect of vaccination on SARS-CoV-2 infection among individuals with type 2 diabetes mellitus (T2DM), cancer, and smoking in a prospective cohort study in Northern Germany. Participants from the SHIP-COVID cohort were followed from October 2020 to October 2022 using repeated questionnaires and serological tests. Infection was defined by anti-nucleocapsid (anti-NCP) antibodies’ detection, self-reported Real Time Polymerase Chain Reaction (RT-PCR) or rapid antigen test. Vaccine efficacy was evaluated using risk differences (RD), risk ratios (RR), p-values, and 95% confidence intervals. Infection risk decreased with more vaccine doses; the 3rd (RR = 0.68) and 4th (RR = 0.29) doses offered significant protection. Both sexes showed protection with 3rd and 4th doses (RR = 0.67 and 0.20 in women and 0.68 and 0.39 in men, respectively). Logistic regression showed higher infection odds in individuals with T2DM (14%) and cancer (68% in SHIP-START-3 dataset and 45% in SHIP-START-4 dataset), while current smokers had 47% and 45% lower odds than non-smokers in SHIP-START-3 and SHIP-START-4 datasets respectively. No significant interactions were found between vaccination and T2DM, cancer, or smoking.